Study summary
Adding blinatumomab to chemotherapy cut relapses in children with standard-risk ALL by about two-thirds
96.0%disease-free at 3 years, vs 87.9% with chemotherapy alone
What was tested
Blinatumomab, a bispecific antibody that links T cells to leukemia cells, added to standard chemotherapy, against chemotherapy alone, for children with newly diagnosed standard-risk B-cell ALL.
What they found
- 3-year disease-free survival was 96.0% vs 87.9%.
- The benefit held in both average-risk (97.5% vs 90.2%) and higher-risk (94.1% vs 84.8%) children.
- Infections were somewhat more common with blinatumomab.
What it means
The trial was stopped early because the benefit was so clear; blinatumomab is now part of first treatment for most children with B-cell ALL.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.